- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06288841
Efficacy and Safety of Liposomal Bupivacaine Under ERAS Concept for Postoperative Analgesia of Ultrasound-Guided QLB in Gynecologic Laparoscopic Patients: A Randomized, Single-blind, Active-Controlled Clinical Study
February 29, 2024 updated by: Ning Luo, Tianjin Medical University General Hospital
With the development of the concept of comfortable medicine and enhanced recovery surgery (ERAS), optimizing the perioperative management of patients, reducing surgical stress, and reducing postoperative pain can effectively reduce perioperative complications and achieve the purpose of accelerating recovery.
As an important part of ERAS, multimodal analgesia is the core concept of perioperative analgesia management.
As a kind of perioperative multimodal analgesia, quadratus lumbar muscle block (QLB) is a type of local anesthetic drug injected around the quadratus lumbar muscle to reduce or eliminate abdominal wall pain and visceral pain after abdominal surgery.
QLB has been used successfully for pain control after laparoscopic and open surgery, reducing perioperative opioid use and improving prognosis-related measures such as PONV and length of hospital stay.
Bupivacaine liposomes use DepoFoam technology to encapsulate the drug in polycystic liposomes, which can prolong the release time of bupivacaine due to the different rupture times of different vesicles, and the postoperative analgesia can be up to 72 hours.
In this project, patients who undergo elective laparoscopic uterine and double adnexectomy were selected to be injected with lipososomes of bupivacaine at different concentrations under ultrasound guidance of bilateral posterior QLB before anesthesia induction, and the effect of liposomal bupivacaine on postoperative pain was investigated by evaluating the postoperative pain and incidence of adverse events.
This study will greatly promote the clinical promotion and application of bupivacaine liposome, improve the postoperative comfort and satisfaction of patients, and accelerate the postoperative recovery of patients.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
200
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Ning Luo
- Phone Number: 13622098703
- Email: ningluo1996@163.com
Study Locations
-
-
Tianjin
-
Tianjin, Tianjin, China, 300052
- Recruiting
- Tianjin Medical University General Hospital
-
Contact:
- Ning Luo
- Phone Number: 13622098703
- Email: ningluo1996@163.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- 1) Age 18-65 years; 2) ASA grade I or II; 3) Patients who are scheduled to undergo elective laparoscopic hysterectomy or laparoscopic hysterectomy and double adnexectomy; 4) BMI of 19-29 kg/m2; 5) Patients who voluntarily sign the informed consent form.
Exclusion Criteria:
- 1) Those who are known to be allergic to the drug components of this study and have allergic constitution; 2) History of allergy to general anesthetic drugs, opioids, and non-steroidal drugs; 3) Patients who need to switch to laparotomy for various reasons; 4) history of neurological disease; History of chronic pain; drug addiction and alcohol abuse; History of long-term opioid use; Opioids are given 48 hours before surgery; 5) ASA grade III or IV; 6) Coronary heart disease, bronchial asthma, severe hypertension, severe hematologic dysfunction, liver and kidney function, and obvious abnormalities in electrolytes; 7) Patients with severe gastrointestinal diseases; 8) Patients who refuse to use intravenous PCIA for analgesia; 9) Pregnant or lactating women; 10) Patients with infection in the skin of the abdominal injection area; 11) Patients with rheumatoid or inflammatory arthritis or diseases requiring chronic analgesic treatment; 12) Patients who have been treated for deep vein thrombosis, pulmonary embolism, myocardial infarction or ischemic stroke in the past 6 months; 13) Those who have poor compliance and cannot complete the test according to the research protocol; 14) Those who have participated in clinical trials of other drugs in the past 4 weeks; 15) Any circumstances that, in the opinion of the investigators, are not suitable for inclusion.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Ropivacaine injection group
|
Ultrasound-guided bilateral QLB2 was performed using Ropivacaine injection prior to anesthesia induction
Other Names:
|
Experimental: Bupivacaine liposomal low-dose group
|
Ultrasound-guided bilateral QLB2 was performed using Bupivacaine liposome injection prior to anesthesia induction
Other Names:
|
Experimental: Bupivacaine liposomal medium-dose group
|
Ultrasound-guided bilateral QLB2 was performed using Bupivacaine liposome injection prior to anesthesia induction
Other Names:
|
Experimental: Bupivacaine liposomal high-dose group
|
Ultrasound-guided bilateral QLB2 was performed using Bupivacaine liposome injection prior to anesthesia induction
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
NRS pain score within 72 hours after surgery
Time Frame: Postoperative (starting from the end of the operation) 2 hours (h), 4h, 6h, 8h, 12h, 24h, 48h, 72h
|
After surgery (starting from the end of surgery), NRS was evaluated at 2h, 4h, 6h, 8h, 12h, 24h, 48h, and 72h
|
Postoperative (starting from the end of the operation) 2 hours (h), 4h, 6h, 8h, 12h, 24h, 48h, 72h
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 30, 2023
Primary Completion (Estimated)
July 31, 2024
Study Completion (Estimated)
November 29, 2024
Study Registration Dates
First Submitted
February 25, 2024
First Submitted That Met QC Criteria
February 29, 2024
First Posted (Actual)
March 1, 2024
Study Record Updates
Last Update Posted (Actual)
March 1, 2024
Last Update Submitted That Met QC Criteria
February 29, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TJMZ2023-008
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pharmacological Action
-
Universidad Nacional de SaltaFundacion Mundo SanoNot yet recruitingPharmacological Action
-
Federal State Budgetary Scientific Institution,...The League of Clinical Research, Russia; Institute of Biomedical Chemistry,...Completed
-
Masaryk Hospital Usti nad LabemUnknownPharmacological ActionCzechia
-
Ervin TasoUniversity of BelgradeCompletedPharmacological ActionSerbia
-
Qin ZhangRecruitingPharmacological ActionChina
-
Food and Nutrition Research Institute, PhilippinesAteneo de Manila University; De La Salle Medical and Health Sciences InstituteActive, not recruiting
-
Fudan UniversityShanghai First Maternity and Infant Hospital; Women and children's hospital...UnknownPharmacological ActionChina
-
Kolding SygehusUnknown
-
University of MalayaMinistry of Health, MalaysiaUnknownPharmacokinetics | Molecular Mechanisms of Pharmacological ActionMalaysia
-
Balance TherapeuticsCompletedMolecular Mechanisms of Pharmacological ActionUnited Kingdom
Clinical Trials on Ropivacaine injection
-
Hvidovre University HospitalUnknownPain, PostoperativeDenmark
-
Chuncheon Sacred Heart HospitalNot yet recruiting
-
Chuncheon Sacred Heart HospitalNot yet recruitingAnterior Cruciate Ligament Rupture | Femoral Nerve BlockKorea, Republic of
-
Chuncheon Sacred Heart HospitalNot yet recruiting
-
Chuncheon Sacred Heart HospitalNot yet recruitingAnterior Cruciate Ligament Rupture | Femoral Nerve BlockKorea, Republic of
-
Zhujiang HospitalCompletedGastrointestinal DiseaseChina
-
Henri Mondor University HospitalNot yet recruitingNeurologic Disorder | Gait, Hemiplegic | Block | Spastic Hemiplegia
-
Centre Hospitalier Universitaire Saint PierreUniversité Libre de BruxellesWithdrawnNerve Entrapment Syndrome | Cluneal SyndromeBelgium
-
University of PittsburghTerminatedOpioid Tolerance, Opioid Naive, Opioid ExposureUnited States
-
Vanderbilt University Medical CenterDuke UniversityWithdrawnMastectomy | Nerve Block | Analgesia, PostoperativeUnited States